Breaking News

Statement by US Secretary of Labor Walsh on November Jobs Report B-21 Raider makes public debut; will become backbone of Air Force’s bomber fleet > Air Force > Article Display Africa-U.S.: Commercial Ties will Shape the Partnership in the 21st Century Readout of Secretary Raimondo’s Meeting with Mexican Secretary of Economy Raquel Buenrostro Readout of Secretary Raimondo’s Meeting with French Minister of the Economy, Finance, and Industrial and Digital Sovereignty Bruno Le Maire US Department of Labor finds Family Dollar Stores again exposing workers to fire, entrapment, struck-by hazards, this time at Richmond Hill location The 91st Annual California State Capitol Tree Lighting Ceremony Heightened Financing, Women and Youth Participation Vital for Peace Efforts, Speakers Tell Economic and Social Council, Peacebuilding Commission

Issued: London UK

GlaxoSmithKline (GSK) today confirmed that on behalf of the European Medicines Agency (EMA), the Committee for Medicinal Products for Human Use (CHMP) has concluded that the available data are insufficient to demonstrate a causal relationship between Pandemrix and the observed cases of narcolepsy. The CHMP has further concluded that any temporary restriction on the use of Pandemrix is not considered warranted.

The CHMP has recommended that all ongoing analyses continue, most notably in Sweden and Finland, where the majority of cases of narcolepsy have been reported. In addition, the CHMP has recommended that the current investigation be expanded to incorporate epidemiological analysis.

The total number of cases of narcolepsy following immunization with Pandemrix reported to GSK as of 0800h GMT on 17 September 2010 was 80, the majority of which were from Sweden and Finland.

“Patient safety is of paramount importance to GSK. In addition to working closely with the regulatory authorities, including EMA, we will also continue our own investigation in an effort to gather additional data and information regarding the reported cases,” said Norman Begg, Chief Medical Officer, GSK Biologicals.

To date, over 30 million doses of Pandemrix have been administered throughout Europe, with the most recent EMA Pharmacovigilance Report1 (19 August 2010) concluding that the benefit-risk profile of the three centrally-approved H1N1 vaccines, including Pandemrix, continues to be positive.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit


122nd Pandemic Pharmacovigilance Weekly Update (EMA/527985/2010); 19 August 2010.

GlaxoSmithKline Enquiries:


UK Media enquiries:

David Mawdsley

(020) 8047 5502


Claire Brough

(020) 8047 5502


Stephen Rea

(020) 8047 5502


Alexandra Harrison

(020) 8047 5502


Jo Revill

(020) 8047 5502




US Media enquiries:

Nancy Pekarek

(919) 483 2839


Mary Anne Rhyne

(919) 483 2839


Kevin Colgan

(919) 483 2839


Sarah Alspach

(919) 483 2839



European Analyst/Investor enquiries:

Sally Ferguson

(020) 8047 5543


Gary Davies

(020) 8047 5503


US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419


Jen Hill Baxter

(215) 751 7002

Source link